Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects who have advanced, recurrent or refractory FRα overexpressing tumors
NCT #
NCT05001282
Condition(s)
Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer
Molecular Target(s)
DNA topoisomerase I
Drug Classification(s)
C'Dot drug conjugate
Agents(s)
ELU001
Phase(s)
I/II
Mechanism of Action
ELU001 is a 7 nm size silica particle that has attached folate molecules to bind to cells with folate receptor in order to deliver the attached cytotoxic payload molecules..
Purpose
- How much of the study can be given with an acceptable level of side effects
- The effects of the study (good and bad)
- How much of the study is absorbed into the blood and how fast it is removed
- If research tests can be used in the future to predict who will benefit from ELU001
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.